Overexpression or hyperactivation of SIRT1 is closely associated with poor prognosis, metastasis, chemoresistance, and oxidative stress resistance in multiple cancer types, including ovarian, liver, breast, and lung cancers. Here, SIRT1 is linked to lung cancer.